Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
|Articles|April 1, 2015
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company that offers innovative gastroenterology treatments.
Advertisement
PRESS RELEASE
LAVAL, Quebec
,
April 1, 2015
/PRNewswire/ --
Valeant Pharmaceuticals International, Inc.
(NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of
Salix Pharmaceuticals, Ltd.
Salix Pharmaceuticals
is a specialty pharmaceutical company that offers innovative gastroenterology treatments such as XIFAXAN® (rifaximin) 550 mg, RUCONEST® (C1 esterase inhibitor [recombinant]), APRISO® (mesalamine), UCERIS® (budesonide) extended release tablets and RELISTOR® (methylnaltrexone bromide).
About
Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc.
(NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about
Valeant Pharmaceuticals International, Inc.
can be found at
Advertisement
Related to this article
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
3
Adult Respiratory Vaccination Delivers Up to $12 in Societal Value for Every $1 Spent, Analysis Finds
4
Biologic Stewardship: The Next Frontier for Health System Pharmacists
5